The European VC (EUVC)
Charles Dunn & Ruth McKernan, SV Health Investors: Exit of the Year Winners and Biotech Company Builders
The European VC (EUVC)
•December 9, 2025•49 min
0
The European VC (EUVC)•Dec 9, 2025
Key Takeaways
- •iBio sold for $1.3B upfront, up to $3B total.
- •SV Health creates biotech firms across development stages, diversifying risk.
- •Europe’s academic strength fuels biotech, but ecosystem still maturing.
- •Neuroscience, especially psychiatry, now attracting more investment than oncology.
- •AI-driven speech analytics accelerates depression diagnosis and fundraising.
Pulse Analysis
SV Health Investors, a transatlantic specialist in healthcare, recently celebrated a landmark exit when iBio was sold to Merck for $1.3 billion upfront, with potential earn‑outs reaching $3 billion. The firm’s strategy blends late‑stage venture investing with in‑house company creation, allowing it to fund drugs from early scientific discovery through Phase III trials. By maintaining a portfolio of 12‑15 companies per fund, SV Health spreads risk across high‑return early projects and lower‑risk late‑stage assets, delivering a balanced return profile for limited partners. This model also attracts strategic partners seeking co‑development opportunities.
Europe’s research landscape provides a strong foundation for biotech, with four of the world’s top ten universities located in the UK. Yet the region still lacks a fully integrated ecosystem that can translate academic breakthroughs into commercial drug programs. SV Health leverages this talent pool, especially in neuroscience and psychiatry, where unmet medical needs and emerging biomarkers are creating new investment opportunities. While oncology remains robust, investors are shifting focus toward mental‑health therapies because patient stratification tools are finally mature enough to de‑risk clinical development.
The firm also embraces artificial intelligence to accelerate discovery and communication. Speech‑analytics platforms now quantify subtle vocal cues, helping clinicians diagnose depression more objectively. In fundraising, large language models can transform hour‑long technical interviews into concise Q&A briefs in minutes, as demonstrated during DRIG’s seed round. These AI‑driven efficiencies reduce time‑to‑insight and improve investor understanding of complex modalities. As biotech capital returns to market, SV Health’s blend of scientific depth, diversified risk, and cutting‑edge digital tools positions it to capture the next wave of high‑impact therapeutics.
Episode Description
Andreas Munk Holm opens the episode by introducing Charles Dunn, Principal at SV Health Investors, and Ruth McKernan, CBE and Operating Partner at SV Health, former CEO of Innovate UK. SV Health is a transatlantic healthcare specialist with a focus on company creation and full-spectrum biotech investing. Notable wins include the exit of SV-created EyeBio to Merck & Co for up to $3bn including $1.3bn upfront, and the recent launch of SV’s newest company creation Driag Therapeutics, a UK-based neuropsychiatry company, which recently announced its $140m Series A financing.
SV Health’s approach blends early-stage company creation with later-stage venture investment. Charles emphasizes that this structure allows:
Diversified risk for LPs: Early-stage opportunities carry higher risk but higher upside; later-stage investments provide more stability.
Learning across stages: Experience in late-stage investing informs early-stage decision-making, and vice versa.
Flexible company formation: SV Health creates companies across different development stages, sometimes even after Phase 1 data exists, as with Draig Therapeutics.
Show Notes
0
Comments
Want to join the conversation?
Loading comments...